{"transactions":[{"id":1384928,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":5287303,"ownership":{"direct":false,"nature":"By Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Northpond Ventures, LP (\"Northpond Fund I\"). Northpond Ventures GP, LLC (\"Northpond GP I\") is the general partner of Northpond Fund I, and Michael P. Rubin is the managing member of Northpond GP I. As a result, each of Northpond GP I and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund I. Each of Northpond GP I and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":471415},"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384927,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":11251624,"ownership":{"direct":false,"nature":"By Northpond Ventures II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Northpond Ventures II, LP (\"Northpond Fund II\").  Northpond Ventures II GP, LLC (\"Northpond II GP\") is the general partner of Northpond Fund II, and Michael P. Rubin is the managing member of Northpond II GP. As a result, each of Northpond II GP and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond II GP and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1003193},"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384926,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":763636,"price":11,"value":8399996.0,"ownership":{"direct":false,"nature":"By Northpond Ventures III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Northpond Ventures III, LP (\"Northpond Fund III\").  Northpond Ventures III GP, LLC (\"Northpond III GP\") is the general partner of Northpond Fund III, and Michael P. Rubin is the managing member of Northpond III GP. As a result, each of Northpond III GP and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III GP and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":763636,"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384925,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":471415,"ownership":{"direct":false,"nature":"By Northpond Ventures, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Northpond Ventures, LP (\"Northpond Fund I\"). Northpond Ventures GP, LLC (\"Northpond GP I\") is the general partner of Northpond Fund I, and Michael P. Rubin is the managing member of Northpond GP I. As a result, each of Northpond GP I and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund I. Each of Northpond GP I and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":471415,"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384924,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1003193,"ownership":{"direct":false,"nature":"By Northpond Ventures II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Northpond Ventures II, LP (\"Northpond Fund II\").  Northpond Ventures II GP, LLC (\"Northpond II GP\") is the general partner of Northpond Fund II, and Michael P. Rubin is the managing member of Northpond II GP. As a result, each of Northpond II GP and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond II GP and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":1003193,"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1648609,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":1,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":2,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":3,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series B Preferred Stock","published_at":"2024-02-12T17:51:02.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":12767776,"ownership":{"direct":false,"nature":"By: Northpond Ventures III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures III GP, LLC (\"Northpond III LLC\") is the general partner of Northpond Ventures III, LP (\"Northpond Fund III\"), and Michael P. Rubin is the managing member of Northpond III LLC.  As a result, each of Northpond III LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2805426},"source":{"system":"sec-edgar","filing":"0000950170-24-014000","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1867627/000095017024014000/ownership.xml","form_type":"4"}},{"id":1648608,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":1,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":2,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":3,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2024-02-12T17:51:02.000Z","date":"2024-02-12","kind":"purchase","planned":false,"acquired":true,"shares":450000,"price":22,"value":9900000.0,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP, LLC (\"Northpond LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond LLC.  As a result, Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Mr. Rubin disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein, if any."}],"balance_after":450000,"source":{"system":"sec-edgar","filing":"0000950170-24-014000","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1867627/000095017024014000/ownership.xml","form_type":"4"}},{"id":1648607,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":1,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":2,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":3,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2024-02-12T17:51:02.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":2805426,"ownership":{"direct":false,"nature":"By: Northpond Ventures III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures III GP, LLC (\"Northpond III LLC\") is the general partner of Northpond Ventures III, LP (\"Northpond Fund III\"), and Michael P. Rubin is the managing member of Northpond III LLC.  As a result, each of Northpond III LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":2805426,"source":{"system":"sec-edgar","filing":"0000950170-24-014000","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1867627/000095017024014000/ownership.xml","form_type":"4"}}]}